ReVue — winback line for independent eye-care practices

1. One-liner

ReVue calls the lapsed eye-care patients your text reminders couldn’t reach, and rebooks the exam plus the eyewear sale.

2. Trend signal — why now?

Three things landed at once.

The voice unlock went commodity. Production-grade voice agents (Retell, Vapi, Bland) are now API primitives. The cost math flipped: a human recall call runs $7–$12 fully loaded; an AI call runs ~$0.40 (Gartner’s contact-center figure). A solo builder can stand up a natural-sounding outbound caller without owning any telephony or speech infrastructure.

Money is flooding into outbound patient reactivation — but at the wrong altitude for independents. Assort Health raised a $76M Series B in October 2025 ($102M total) and launched an outbound agent for recall, referrals, and flu-shot outreach; early deployments report 61% of flu-shot bookings and 64% of referral appointments scheduled through agentic outreach. By Q1 2026, AI voice agents and digital health had pulled $1.8B in funding — 60% of all digital-health VC. These players chase multi-location medical groups on Epic/Athena. Nobody is building the optometry-shaped, single-doctor version.

The optometry recall problem is structurally unsolved and economically enormous. Independent practices lose 20–40% of their patients every year simply because nobody rebooks them. Strong-recall practices report $630 average revenue per patient versus $210 at poor-recall practices — a 3× gap. Every recall in optometry is worth 2–3× a normal medical rebook because it drags an eyewear or contact-lens sale behind it ($300–$500 per visit). The incumbents (Weave, Solutionreach, RevolutionEHR, Jelo) all send text + email blasts only — when the patient ignores the text, the patient is gone. There is no voice layer that picks up where the text dies.

Provenance:

• Signal 1 (demand): Independent practices lose 20–40% of patients annually to missed rebooking; strong recall = 3× revenue per patient ($630 vs $210); incumbents (Jelo $200/mo, Weave/Solutionreach $200–500/mo) send text+email only — https://jeloapp.com/optical-crm , https://mybcat.com/blog/optometry-practice-finances/ , https://boomcloudapps.com/patient-recall-service-for-optometry-how-to-keep-patients-coming-back-and-spending-4x-more/ — 2026-06-02
• Signal 2 (feasibility): Commodity outbound voice agents at ~$0.40/call vs $7–$12 human; FCC/TCPA healthcare exemption permits recall calls to existing patients (1/day, 3/week, with opt-out) — https://www.retellai.com/blog/tcpa-compliance-playbook-voice-ai-outbound , https://www.aoa.org/news/practice-management/perfect-your-practice/the-wrong-patient-communication-plan-could-be-costly — 2026-06-02
• Signal 3 (economic): Assort Health $76M Series B + outbound agent launch (Oct 2025); $1.8B into voice/digital-health in Q1 2026; Brevium claims 20–58× ROI on eye-care reactivation — https://www.fiercehealthcare.com/ai-and-machine-learning/assort-health-rolls-out-outbound-ai-agent-personalized-patient-outreach , https://brevium.com/specialties/optometry/ — 2026-06-02 Category: Tech-unlock

3. The opportunity

The recall market for optometry is owned by messaging tools that mistake “we sent a text” for “we recovered the patient.” That is the gap.

Here is the structural failure, in the words of practice-management literature: “The patient just left the chair. The front desk is busy with the next check-in. Six months pass. Twelve months pass. Eighteen months pass. The practice ‘forgets’ the patient and the patient drifts to the chain optometrist next door.” Weave and friends paper over this with a reminder cadence — 90/60/30/7 days, then a re-engagement sequence. But the re-engagement sequence is just more texts to the same dead number/inbox. For the 60–70% of lapsed patients who don’t respond to text, there is no next step. Calling them is the next step, and no front desk has time to dial 400 dormant patients.

ReVue is the voice layer that does exactly that. It pulls the overdue and dormant lists out of the EHR, calls them with a natural-sounding agent that knows their last exam date and what they’re due for, handles the back-and-forth (“what nights are you open?”, “do you take VSP?”), and books the slot straight into the schedule. It is not an AI receptionist (inbound, saturated). It is an outbound revenue-recovery line aimed at a list of patients the practice has already given up on.

The 10× isn’t “AI can text better.” It’s: the incumbents structurally cannot reach the non-responders, and ReVue’s entire reason to exist is reaching them.

4. Target market

• Primary customer: Owner-optometrist of a 1–3 location independent practice in the US, 1,500–8,000 patients of record, using RevolutionEHR / Crystal PM / Eyefinity / Compulink. The decision-maker IS the doctor — no committee.
• Why they buy: They can see the dormant list in their own EHR and know each line is $300–500 of exam-plus-optical they’re leaving on the table. They’ve already paid Weave/Solutionreach and watched the texts bounce off the dead patients. As one practice put it, December is “the scramble, where people suddenly realize they haven’t used their benefits, and the phones start ringing off the hook” — but only for the patients who remember. ReVue makes the practice the one doing the reminding, by voice, before the chain down the street does.
• Rough TAM reasoning: ~29,000 optometrist businesses in the US; independents hold ~55% of the market. Call it 12,000–15,000 independent practices that are real targets. At even a $399/mo blended ACV, 1,000 practices = ~$4.8M ARR. The serviceable wedge is far smaller than the headline TAM — that’s fine, sub-$5M is the goal.
• Why now for them: Vision visits actually fell 3.1% in 2025 while the pet-, er, patient population grew; revenue growth was a thin 2.5%. Independents are squeezed between chains (LensCrafters/Warby) and rising costs, and a no-CAC channel — patients they already own — is the cheapest revenue they can buy. Plus the year-end FSA/vision-benefit “use it or lose it” cliff makes Q4 recall a literal deadline.

5. Product sketch (MVP)

• One-click overdue/dormant pull from the EHR. Sync patient list, last-exam date, Rx-expiry, contact-lens type, and vision plan from RevolutionEHR / Crystal PM (start with one, add the next two).
• Smart winback segments out of the box: 12–18 month dormant, contact-lens annual-supply-due, and the killer one — year-end vision-benefit-expiry list (patients with unused VSP/EyeMed/FSA benefits that reset Jan 1).
• Outbound AI voice agent that actually talks. Knows the patient’s name, last visit, and what they’re due for; answers “are you open Saturdays?” / “do you take my insurance?”; offers two concrete slots and books into the schedule.
• Voice-first, text-fallback waterfall. Text first (cheap); the patients who ignore it get the call. The call is the product; the text is the warm-up.
• TCPA guardrails baked in: consent + opt-out tracking, frequency caps (1/day, 3/week), DNC scrub, full call recording and transcript log per patient.
• The money dashboard: appointments booked, exams + estimated optical revenue recovered, $ per dollar spent — the ROI number the doctor screenshots for their accountant.
• Two-way calendar write-back so the front desk doesn’t re-key anything.

6. AI angle — what’s load-bearing

Remove the AI and there is no product — it’s just a call center the practice already can’t afford. The load-bearing AI is the conversational outbound voice agent: it has to sound human enough that a 58-year-old presbyope doesn’t hang up, hold a real scheduling negotiation, parse insurance questions, and degrade gracefully to “let me have the office call you.” A reminder blast is a cron job; a voice agent that rebooks a reluctant lapsed patient is the thing that’s newly possible and newly cheap. AI also does the segmentation reasoning — deciding which patients to call, in what order, with what pitch (benefit-expiry urgency vs. CL-reorder convenience).

7. Localization angle

N/A — this is a US-first play. The wedge depends on US-specific structures: vision-plan benefit-year resets (VSP, EyeMed), FSA/HSA “use it or lose it” deadlines, the TCPA healthcare exemption, and US optometry EHRs (RevolutionEHR, Crystal PM, Eyefinity). Those don’t transfer cleanly abroad. There’s a future UK/Australia/Canada cut (different EHRs, different benefit rails), but forcing a localization angle now would dilute the wedge. Build US, deep.

8. Business model — path to $1M–$5M ARR

• Pricing: Base SaaS $299–$499/mo per location (segments, dashboard, integration), plus a usage component on calls/bookings — or a flat $499–$799 “winback” tier that bundles a call allotment. Anchor against the $200–500/mo practices already pay Weave/Solutionreach for text-only, and against the 20–58× ROI Brevium openly advertises in this exact vertical.
• ACV: ~$4,800–$7,200/yr blended.
• Math to $1M ARR: ~175 practices × $480/mo × 12 ≈ $1.0M. Reachable from a single founder-led sales motion in year one.
• Math to $5M ARR: ~870 practices at the same ACV, or fewer with a usage/performance tier that scales with recovered revenue. Needs 2–3 EHR integrations live and a repeatable channel (associations + EHR marketplaces).
• Expansion path: add CL-reorder reactivation, no-show backfill, post-op/medical-eye recall, and a performance tier (% of recovered revenue) for practices that want pure-upside pricing. ACV climbs as you own more of the patient-comms surface the incumbents currently rent out.

9. Go-to-market wedge — first 100 customers

• Run the ROI demo on their own data. Independent ODs will hand you a dormant-patient count if you sign a BAA. Pull 90 days of their overdue list, show “you have 612 patients worth ~$210K of exam+optical that nobody has called,” and offer a paid 60-day pilot to recover a slice. The proof IS the pitch.
• State optometric associations + ODs-on-Facebook groups. ODs cluster in tight private communities (state AOA affiliates, “ODs on Finance,” large practice-management Facebook groups). Sponsor/present a “we recovered $X for Dr. So-and-so” case study. These rooms convert because the audience is exactly the buyer and they gossip.
• EHR marketplace + integration co-marketing. RevolutionEHR/Crystal PM list third-party integrations (Doctora etc. already plug in). Being the “voice recall” app in their marketplace is a warm, repeatable channel.
• Time the year-end cliff. Land pilots in Sept–Oct, ride the Q4 FSA/benefit-expiry scramble as the live demo, convert to annual in January when the recovered-revenue number is undeniable.
• Cold Loom on the dormant list. Scrape practice sites, record a 60-second “here’s roughly how many patients you’re losing” walkthrough, send to 500 owner-ODs. Expect low single-digit reply but high close on the replies — the pain is concrete and the ROI is arithmetic.

10. Build complexity — justification

Medium. The voice agent itself is off-the-shelf (Retell/Vapi + a good prompt and scheduling logic) — that part is weeks. The real work is the EHR integrations (RevolutionEHR, Crystal PM, Eyefinity — varying API quality, some needing data-transfer plumbing), reliable two-way calendar write-back, and the TCPA/consent compliance layer done correctly (frequency caps, opt-out, DNC, recording, BAA). A pair could ship a single-EHR v1 in ~3 months; full credibility (2–3 EHRs + compliance hardened) is a 4–6 month build. No research risk, no custom models, no hardware.

11. Gating checklist

Gate	Pass?	Note
Legal in target market	✅	TCPA healthcare exemption covers recall calls to existing patients (1/day, 3/week, opt-out). Compliance is operating discipline, not a launch blocker.
Ethical — no harm / dark patterns	✅	Calling your own patients to rebook overdue eye care is patient-positive; opt-out is first-class. Cap frequency, no manipulation.
Market exists (evidence above)	✅	Incumbents charge $200–500/mo for text-only; Brevium advertises 20–58× ROI in this exact vertical; 20–40% annual patient loss.
1–5 person team can build this	✅	Off-the-shelf voice + EHR integrations + compliance layer. Medium build.
Launchable with <$50K / ₹40L	✅	Voice API usage is pay-as-you-go; main cost is the founders’ time and EHR integration grind.

All five pass.

12. Feasibility score

Axis	Weight	Score	Notes
Problem intensity	20	16/20	Real, recurring, money-on-the-table pain; 20–40% annual patient bleed. Not quite hair-on-fire daily, but Q4 it is.
Demand evidence	15	13/15	Multiple independent signals: incumbents charging real money (text-only), funded outbound players, advertised 20–58× ROI, hard 3× ARPP stat. A skeptic nods.
Build feasibility	15	11/15	Voice is trivial; EHR integrations + compliance are the gnarly 3–6 month grind.
Distribution clarity	15	12/15	Named buyer, tight communities, EHR marketplaces, on-their-own-data demo. Conversion math is plausible, not yet proven.
Revenue mechanics	15	13/15	Clear pricing anchored to existing spend; ROI is arithmetic; ACV supports sub-$5M with hundreds of practices.
Time to first revenue	10	7/10	Paid pilots possible in weeks, but first EHR integration gates a real deployment — call it 8–12 weeks to first dollar.
Defensibility	10	5/10	Execution + workflow lock-in + EHR integration grind + compliance know-how. Copyable by a funded medical-voice player who decides to point at optometry — that’s the real threat.
Total	100	77/100

13. Qualitative modifiers

Founder-fit tags

technical-heavy (voice + EHR integration + reliable scheduling write-back) · domain-expertise-required (optometry billing/benefit cycles, TCPA healthcare nuance). A technical founder paired with an OD or optometry practice-management advisor is the ideal team.

Key assumptions to validate (3–5)

1. Assumption: Lapsed optometry patients will actually answer and rebook via an AI voice call at a rate that clears the cost of the call. How to test: Run a paid 60-day pilot on 3 practices’ dormant lists; measure connect → book → show-up conversion against the text-only baseline.
2. Assumption: Owner-ODs will pay $300–800/mo on top of their existing reminder tool, not instead of it. How to test: 30 pricing interviews + 3 signed pilots at target price; track whether they keep Weave alongside ReVue.
3. Assumption: EHR integration (RevolutionEHR/Crystal PM) is achievable without a partnership gate. How to test: Build the first read+write integration in <6 weeks; confirm calendar write-back works in a live practice.
4. Assumption: TCPA exemption + consent handling keeps legal risk acceptable. How to test: Healthcare-telecom counsel review of the call flow, consent capture, and opt-out before first live call.

Risk flags

1. Regulatory risk (TCPA): Per-call statutory damages run $500–$1,500 with no aggregate cap if consent/opt-out is botched. The exemption is narrow (existing patients, capped frequency, opt-out). This is the single biggest landmine — compliance must be product-grade, not best-effort.
2. Competitive risk (incin-bound from above): A funded medical-voice player (Assort, Brevium, or a Weave) could point its existing outbound engine at optometry and erase the wedge. Speed + optometry-specific depth (benefit cycles, CL reorders, optical revenue) is the only defense.
3. Platform dependency: Two-sided reliance — on EHR APIs (could close or charge) and on voice infra (Retell/Vapi pricing/quality). Mitigate with multi-provider voice and at least two EHR integrations early.
4. Channel/trust risk: ODs are conservative buyers; one creepy-sounding AI call to a beloved long-time patient can torch a reference. Voice quality and tone are existential, not cosmetic.

14. Structured verdict

Score:                  77/100
Verdict:                GO
Confidence:             Medium
Best-fit builder:       Technical founder + optometry/practice-management advisor (or OD co-founder)
Time to revenue:        8–12 weeks (paid pilot), first integrated deployment by ~month 3
Capital to launch:      ₹8–15 lakh / $10–18K (mostly time; voice usage is pay-as-you-go)
Top 3 assumptions to validate first:
  1. Lapsed patients answer + rebook via AI voice above cost — paid 60-day pilot, measure book/show vs text baseline
  2. Owner-ODs pay $300–800/mo on top of existing reminder tool — 30 interviews + 3 signed pilots
  3. RevolutionEHR/Crystal PM read+write integration ships in <6 weeks with working calendar write-back
Kill criteria:
  - Abandon if <12% of called lapsed patients (12–18mo dormant) book a real appointment in pilot
  - Abandon if first EHR integration can't reliably write appointments back after 8 weeks of effort
  - Abandon if a funded medical-voice incumbent ships an optometry-specific outbound product before your v1

15. Next step — 1-week validation sprint

• Day 1–2: Recruit 3 friendly independent ODs (state-association/Facebook groups). Sign BAAs. Pull each one’s 12–18 month dormant list and the year-end benefit-expiry segment; quantify the dollars sitting in each list. This alone tells you if the pain is real to them.
• Day 3–4: Stand up a single-segment voice agent (Retell/Vapi) loaded with one practice’s overdue list and real availability. Make 50 supervised live calls. Capture connect rate, booking rate, and — critically — listen for the tone failures.
• Day 5: Decide on a hard number. Go if ≥12% of called dormant patients book a real appointment AND ≥2 of 3 ODs commit to a paid pilot at ≥$399/mo. Below that, the voice channel isn’t beating the text baseline enough to justify the build — go back to signals.

The result is falsifiable: a booking rate and a signed-pilot count, not a vibe.